Tablets & Capsules


Issue link:

Contents of this Issue


Page 7 of 51

6 October 2020 Tablets & Capsules research FDA publishes Rx pharmaceutical products quality testing study SILVER SPRING, MD—The FDA published a study "Quality Testing of Difficult-to-Make Prescription Phar- maceutical Products Marketed in the US," the largest sampling study of pharmaceutical manufacturers for the US market to date. According to the study, 252 drug products sam- pled met the US market standards for quality attributes of dosage unit uni- formity and dissolution, although the data also suggest that the consistency of these attributes differs between regions and manufacturers. Research- ers also identified opportunities for regulatory outreach to improve the quality of the US prescription phar- maceutical supply. The study was published in the Journal of the American Medical Association Network Open. markets Pharmaceutical traceability market to grow 21 percent annually through 2024 ELMHURST, IL—The pharmaceu- tical traceability market is forecast to grow at a compound annual rate of 21 percent through 2024, reaching $4.18 billion, according to a report from Infinity Research. Increasing concerns about counterfeit drug products and rapid growth in drug development is expected to drive market growth. The study also identified blockchain tech- nology and the rise of pharmaceuti- cal outsourcing as drivers of increased market demand. Global capsule filler market to reach $1 billion by 2027 ALBANY, NY—The global cap- sule filler market is expected to reach about $1 billion by the end of 2027, according to a report by Transparency Market Research. Crucial factors driv- ing growth include increasingly strict government regulation of pharmaceu- ticals around the world and continued growth in the popularity of capsule dosage forms. The report identifies ACG, Capsugel, Glenvale Packag- ing, Harro Hofliger, IMA, MG Amer- ica, Qualicaps, Riva Europe, Schaefer Technologies, and Syntegon as key market players. industry news FDA promotes DMFs to support cannabis research SILVER SPRING, MD—The FDA is encouraging stakeholders researching cannabis and cannabis-derived drugs to use Drug Master Files (DMFs) to protect proprietary information while participating in drug development. The DMF pathway allows parties to submit confidential and detailed information on the facilities, processes, and materi- als they are using to manufacture, pro- cess, package, and store their products. This announcement comes on the heels of the FDA draft guidance on canna- bis and cannabis- derived compounds. LIS-LABO PIONEER IN UV LASER PRINTING TECHNOLOGY PROGRESS BEYOND TRADITIONAL INK WHY UV LASER? • Higher print quality improving product brand recognition • .001% defect rate, eliminating traditional ink printing errors • Quick set-up with user friendly CAD system • Easy to clean, reducing overall manufacturing cost • Larger print area • Superior anti-counterfeiting method • Available in lab and commerical scale models QUALIS

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC1020